{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:30:26Z","timestamp":1787016626531,"version":"build-2736575974"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Expanded options for treatments directed against pathogens that can be used for bioterrorism are urgently needed. Treatment regimens directed against such pathogens can be identified only by using data derived from in vitro and animal studies. It is crucial that these studies reliably predict the efficacy of proposed treatments in humans. The objective of this study was to identify a levofloxacin treatment regimen that will serve as an effective therapy for\n                    <jats:italic>Bacillus anthracis<\/jats:italic>\n                    infections and postexposure prophylaxis. An in vitro hollow-fiber infection model that replicates the pharmacokinetic profile of levofloxacin observed in humans (half-life [\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    ], 7.5 h) or in animals, such as the mouse or the rhesus monkey (\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    , \u223c2 h), was used to evaluate a proposed indication for levofloxacin (500 mg once daily) for the treatment of\n                    <jats:italic>Bacillus anthracis<\/jats:italic>\n                    infections. The results obtained with the in vitro model served as the basis for the doses and the dose schedules that were evaluated in the mouse inhalational anthrax model. The effects of levofloxacin and ciprofloxacin treatment were compared to those of no treatment (untreated controls). The main outcome measure in the in vitro hollow-fiber infection model was a persistent reduction of culture density (\u22654 log\n                    <jats:sub>10<\/jats:sub>\n                    reduction) and prevention of the emergence of levofloxacin-resistant organisms. In the mouse inhalational anthrax model the main outcome measure was survival. The results indicated that levofloxacin given once daily with simulated human pharmacokinetics effectively sterilized\n                    <jats:italic>Bacillus anthracis<\/jats:italic>\n                    cultures. By using a simulated animal pharmacokinetic profile, a once-daily dosing regimen that provided a human-equivalent exposure failed to sterilize the cultures. Dosing regimens that \u201cpartially humanized\u201d levofloxacin exposures within the constraints of animal pharmacokinetics reproduced the antimicrobial efficacy seen with human pharmacokinetics. In a mouse inhalational anthrax model, once-daily dosing was significantly inferior (survival end point) to regimens of dosing every 12 h or every 6 h with identical total daily levofloxacin doses. These results demonstrate the predictive value of the in vitro hollow-fiber infection model with respect to the success or the failure of treatment regimens in animals. Furthermore, the model permits the evaluation of treatment regimens that \u201chumanize\u201d antibiotic exposures in animal models, enhancing the confidence with which animal models may be used to reliably predict the efficacies of proposed antibiotic treatments in humans in situations (e.g., the release of pathogens as agents of bioterrorism or emerging infectious diseases) where human trials cannot be performed. A treatment regimen effective in rhesus monkeys was identified.\n                  <\/jats:p>","DOI":"10.1128\/aac.49.12.5099-5106.2005","type":"journal-article","created":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T16:57:58Z","timestamp":1132678678000},"page":"5099-5106","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":66,"title":["Effective Antimicrobial Regimens for Use in Humans for Therapy of\n                    <i>Bacillus anthracis<\/i>\n                    Infections and Postexposure Prophylaxis"],"prefix":"10.1128","volume":"49","author":[{"given":"Mark R.","family":"Deziel","sequence":"first","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Heine","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Louie","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kao","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Byrne","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Basset","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Miller","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bush","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kelly","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. L.","family":"Drusano","sequence":"additional","affiliation":[{"name":"Ordway Research Institute, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1665-1670.2002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.56.012302.160616"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.6.1386"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2523"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0906.030118"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068474"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/319281"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.464-470.2002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.483"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/383320"},{"key":"e_1_3_2_14_2","first-page":"475","volume":"58","year":"1940","unstructured":"Eagle, H., and A. D. Musselman. 1940. The slow recovery of bacteria from the toxic effect of penicillin. J. Bacteriol.58:475-490.","journal-title":"J. Bacteriol."},{"key":"e_1_3_2_15_2","first-page":"382","year":"1986","unstructured":"Edberg, S. C. 1986. The measurement of antibiotics in human body fluids: techniques and significance, p. 382-399. In V. Lorian (ed.), Antibiotics in laboratory medicine, 2nd ed. The Williams & Wilkins Co., Baltimore, Md.","journal-title":"Antibiotics in laboratory medicine"},{"key":"e_1_3_2_16_2","first-page":"37988","volume":"67","year":"2002","unstructured":"Federal Register. 2002. Fed. Regist.67:37988-37998.","journal-title":"Regist."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.9.1905"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316814"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0302.970201"},{"key":"e_1_3_2_22_2","unstructured":"Kelley M. et al. 2003. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. abstr. B331A."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Leary R. R. Jelliffe A. Schumitzky and M. van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK\/PD) models p. 389-392. In Proceedings of the 14th IEEE Symposium on Computer Based Medical Systems. IEEE Computer Society Bethesda Md.","DOI":"10.1109\/CBMS.2001.941750"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/20014091096774"},{"key":"e_1_3_2_25_2","unstructured":"National Committee for Clinical Laboratory Standards. 1997. Document M7-A4. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.125"},{"key":"e_1_3_2_27_2","unstructured":"U.S. Food and Drug Administration. 2002. Draft guidance for industry inhalational anthrax (post-exposure)\u2014development of antimicrobial drugs. CDER U.S. Food and Drug Administration Washington D.C."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3201\/eid0809.010536","volume":"8","year":"2002","unstructured":"Wheelis, M. 2002. Biological warfare at the 1346 siege of Caffa. Emerg. Infect. Dis.8:971-975.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_30_2","first-page":"1","volume":"45","year":"1999","unstructured":"Worsham, P. L., and M. R. Sowers. 1999. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can. J. Microbiol.45:1-8.","journal-title":"Can. J. Microbiol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00006-1"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.12.5099-5106.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.12.5099-5106.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T16:02:06Z","timestamp":1736092926000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.12.5099-5106.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1128\/AAC.49.12.5099-5106.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.12.5099-5106.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"2005-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-09-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}